Kornimate/medical-research-clean huggingface dataset:
telephone based cognitive behavioral therapy for hiv related depression

Conditions: Depression; HIV Infections

Summary: the purpose of this study is to evaluate the effectiveness of a telephone-based, cognitive behavioral therapy intervention in the treatment of depression in adults diagnosed with hiv.

up to 40% of individuals receiving medical care for hiv meet dsm-iv criteria for co-occurring depressive disorder. individuals with hiv and depressive disorders, compared to those with hiv alone, have been shown to have worse adherence to taking antiretroviral medication, increased hiv related morbidity and among women a higher mortality. previous research suggests that mental health interventions may lead to improved depressive and hiv related outcomes. however because many hiv infected depressed individuals may have trouble accessing mental health services, there is an urgent need for treatment trials to assess whether treatment of depression targeting patients in urban hiv care settings will result in both improved depressive and hiv related outcomes. the goal of this project is to test the preliminary effectiveness of an adapted telephone-based, cognitive behavioral therapy (cbt) intervention targeting hiv infected depressed individuals receiving care in adult outpatient hiv clinics. a total of 60 hiv infected, depressed individuals receiving care at an urban, outpatient hiv clinic will be randomly assigned to receive either the telephone psychotherapy intervention or enhanced usual care with non-specific telephone contact. the results will provide preliminary data on whether the telephone psychotherapy intervention for hiv infected depressed individuals is effective in reducing depression. the results will also be used to determine feasibility, accessibility, and whether the intervention leads to improved retention and better satisfaction.

Eligibility criteria:
inclusion criteria: * has a dsm-iv diagnosis of a depressive disorder as measured by the mood battery of the mini * has a diagnosis of hiv and is receiving hiv related outpatient care at the evelyn jordan center in baltimore, md * is able to speak english * is able to read english on approximately the 6th grade reading level or higher as measured by the wide range achievement test 4 (wrat-4) or by self-report * is at least 18 years old * has access to a telephone exclusion criteria: * meets criteria for dementia by scoring below 10 on the hopkins hiv dementia scale * shows signs of serious psychiatric pathology that might either be due to an organic etiology other than hiv, or would generally not be considered treatable solely with psychotherapy, or for whom participation in this protocol might be considered dangerous or unethical * has a history of serious suicide attempts or is severely suicidal (has ideation, plan, and intent) determined by the mini * patients in psychotherapy are excluded because it is confounded with the study treatments

Keywords: hiv
msg and gastrointestinal motility

Conditions: Gastroesophageal Reflux

Summary: the purpose of this study is to clarify the physiological function of sodium glutamate by measuring its effect on upper gi motility ( gastric emptying).

amino acids such as monosodium glutamate are known to stimulate both endocrine and exocrine secretion. in addition, there is a report that oral intake of glutamate evokes the activation of vagal afferent nerves in the rat. thus, such amino acids are thought to be influential in the process of digestion and absorption. . to investigate the effect of monosodium glutamate on gastrointestinal motility, we planned a single-blind randomized study. the participants will take either monosodium glutamate or sodium chloride before the first examination of upper gi motility and the other agent before the second examination. the order of intake will be randomized by the envelope method.

Eligibility criteria:
inclusion criteria: * healthy subjects * must not have digestive symptoms * must not eat within six hours of study participation exclusion criteria: * regular medications for the gastrointestinal tract * previous helicobacter pylori infection * previous abdominal surgery

Keywords: gastrointestinal motility gastroesophageal reflux gastric emptying sodium glutamate lower esophageal sphincter
a study of the use of chartis system to optimize subject selection for endobronchial lung volume reduction (elvr)

Conditions: Emphysema

Summary: use of the chartis® assessment system prior to ebv treatment

this is a multi-center study which will enroll up to 120 patients. subjects will undergo a chartis assessment prior to ebv treatment. the chartis assessment will determine the presence or absence of collateral ventilation, a potential determining factor in the success of ebv therapy. this study is not randomized; all subjects are eligible to receive ebv treatment, regardless of chartis assessment outcome. follow-up data will only be collected on those patients that meet the chartis inclusion criteria.

Eligibility criteria:
inclusion criteria: * heterogeneous emphysema * able to obtain a chartis value during assessment exclusion criteria: * any co-existing major medical problems that would not make it possible for the subject to tolerate a bronchoscopic procedure.
tadalafil and lenalidomide maintenance with or without activated marrow infiltrating lymphocytes (mils) in high risk myeloma

Conditions: Multiple Myeloma

Summary: this research is being done to find out if altering the immune system by giving activated marrow infiltrating lymphocytes (mils) can improve outcomes for multiple myeloma patients who receive a standard autologous stem cell transplant.


Eligibility criteria:
inclusion criteria: * age 18 - 80 years old; * patients with active myeloma requiring systemic treatment; * newly diagnosed patients. relapsed myeloma patients that have not previously had a transplant; * meeting criteria for high-risk disease; * measurable serum and/or urine m-protein from prior to induction therapy documented and available. a positive serum free lite assay is acceptable; * eastern cooperative oncology group (ecog) performance status of 0 - 2 (see appendix c). * meet all institutional requirements for autologous stem cell transplantation; * the patient must be able to comprehend and have signed the informed consent; * patients must have had \> than pr after last therapy. exclusion criteria: * diagnosis of any of the following cancers: * poems syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein \[m-protein\] and skin changes); * non-secretory myeloma (no measurable protein on serum free lite assay); * plasma cell leukemia; * diagnosis of amyloidosis; * failed to achieve at least a partial response (pr) to latest therapy; * previous hematopoietic stem cell transplantation;patients can have had prior relapsed disease as long as they have never been previously transplanted; * known history of hiv infection; * use of corticosteroids (glucocorticoids) within 21 days of bone marrow collection; * use of any myeloma-specific therapy within 21 days of bone marrow collection; * infection requiring treatment with antibiotics, antifungal, or antiviral agents within seven days of registration; * participation in any clinical trial within 28 days of registration on this trial, which involved an investigational drug or device; * history of malignancy other than multiple myeloma within five years of registration, except adequately treated basal or squamous cell skin cancer; * active autoimmune disease (e.g., rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosis) requiring active systemic treatment. hypothyroidism without evidence of grave's disease or hashimoto's thyroiditis is permitted. * human t-lymphotropic virus (htlv) 1 or 2 positive; * known hypersensitivity to prevnar or any of its components; * contraindication to phosphodiesterase-5 inhibitors (e.g. currently on nitrates).
effect of vojta therapy on covid-19 respiratory disease

Conditions: COVID-19 Acute Respiratory Distress Syndrome

Summary: vojta therapy is a physiotherapy intervention with scientific evidence in respiratory pathologies in children and proven in adults. in this pilot study with an rct design, its effect in adult patients with respiratory pathology caused by the sars-cov-2 virus will be studied. the non-invasive and non-painful technique consists of applying tolerable pressure to specific areas of the patient's body. the objective is to activate, in a reflex way, the ventilatory physiology. it is compared with the conventional respiratory physiotherapy approach.


Eligibility criteria:
inclusion criteria: * respiratory disease by covid-19 exclusion criteria: * patient older than 75 years

Keywords: vojta therapy respiratory physiotherapy
identifying novel biomarkers in early rheumatology patients

Conditions: Rheumatologic Disorder

Summary: patients new to a rheumatology practice will be asked if they want to consent to their blood sample, medical records, and hand/foot x-rays (with sharp scores) for the analysis and correlation with the diagnosis they will receive from the rheumatologist.

at the end of their first visit new rheumatology patients will be asked for their interest in joining the inova biomarker study. if yes, the patient will be consented, blood will be drawn for the inova biomarkers, and x-rays will be sent for sharp scoring. patients may decline and will not be part of the inova study. patients who decline will continue to receive standard of care treatment henceforth. patients in the inova trial will receive a diagnosis from their doctor and are placed into separate cohorts based upon their diagnosis. the inova biomarker results of each cohort will be cross-correlated with diagnoses, pre-screening tool results. baseline disease activity and sharp scores will also be correlation variables.

Eligibility criteria:
inclusion criteria: * newly referred arthritis northwest pllc * age 18 or older exclusion criteria: * none.
humanitarian device exemption

Conditions: Dystonia

Summary: the purpose of this study is to allow patients to undergo deep brain stimulation (dbs) surgery for the treatment of dystonia. this is not a research study, but rather, a requirement by the fda for humanitarian use of the deep brain stimulator device in the treatment of this rare disorder. use of dbs for dystonia is approved for humanitarian use by the fda in the treatment of chronic, intractable (drug refractory) dystonia, including generalized and segmental dystonia, hemidystonia, and cervical dystonia (torticollis) in patients 7 years or older. thus, this proposal request authorization by the irb to allow patients at vumc to access this hud therapy.

the purpose of this irb approved study is to allow patients to undergo deep brain stimulation (dbs) surgery for the treatment of dystonia. this is not a research study, but rather, a requirement by the fda for humanitarian use of the deep brain stimulator device in the treatment of this rare disorder. use of dbs for dystonia is approved for humanitarian use by the fda in the treatment of chronic, intractable (drug refractory) dystonia, including generalized and segmental dystonia, hemidystonia, and cervical dystonia (torticollis) in patients 7 years or older. thus, this proposal request authorization by the irb to allow patients at vumc to access this hud therapy.

Eligibility criteria:
inclusion criteria: * patients whose ages are in the range of 7 and 99 years old * patients who are diagnosed with chronic, intractable (drug refractory)primary dystonia, including generalized and or segmental dystonia, hemidystonia, and cervical dystonia (torticollis)as determined by a neurologist or neurosurgeon. * patients who have failed appropriate medical therapy as determined by the smd conference exclusion criteria: * patients younger than 7 years old * patients who are at significant surgical risk as determined by the neurosurgeon and/or anesthesiologist. * patients who have not had an adequate trial of medical or non-surgical therapy as determined by the smd conference. * patients not deemed good candidates by the smd conference group.

Keywords: dystonia dbs
ubiquitous healthcare for elderly patients with type 2 diabetes mellitus

Conditions: Diabetes

Summary: ubiquitous healthcare service for elderly patients with type 2 diabetes provides real-time glycemic monitoring and glucose control implemented by clinical decision support system (cdss) using wire and wireless communication and information technology. to evaluate the clinical efficacy of this system, researchers plan to compare the improvement of glycemic control, self-management, and quality of life among three study groups: control, self glucose monitoring, and u-healthcare group.

recently, the application of internet-based glucose control system showed better long term glucose control compared to the conventional treatment. this study has become the foundation of web-based methodology in the glucose control. in addition, the combined application of mobile device and web-based monitoring system for chronic diseases showed improvement in various metabolic parameters in obese patients with diabetes and hypertension. thus, the application of u-healthcare based on advanced information technology would be helpful in the diabetes management. we plan to provide an individualized u-healthcare service using advanced information technology that enables more effective glucose control.

Eligibility criteria:
inclusion criteria: * type 2 diabetes * age: 60 \~ 85 yrs * hba1c: 6.5%-11.0% * duration of diabetes: less than 30 years * bmi: 20-35 exclusion criteria: * systemic corticosteroid administered within previous 6 months * history of myocardial ischemia * heart failure, nyha class ii-iv * thyroid disease with abnormal tft * anti-obesity drugs or slimming products within previous 3 months
efficacy of slt in patients with insufficient iop control under maximum tolerated drug therapy (eye drops)

Conditions: Glaucoma

Summary: examination and follow-up of efficacy and safety of slt in patients with unsufficient iop control despite maximum tolerated topical therapy. in addition, it will be examined whether medical treatment can be reduced after the slt procedure and whether filtering surgery - as the only remaining option - may be postponed.

slt (selective laser trabeculoplasty) uses the nd:yag-lasers (wavelength 532nm, q-switched, frequency-doubled). thanks to the low laser energy used and the short duration of treatment, only pigmented cells of the trabecular meshwork are targeted and selectively treated. neighboring, non-pigmented cells and tissue are spared collateral and thermic damage, the architecture of the trabecular meshwork remains intact. the slt procedure uses less than 1% of the energy of the alt procedure with an extremely low pulsation duration. several studies confirm the effective iod reduction of slt and rate the procedure as an relatively safe and effective therapy for glaucoma. also repeated use of the slt procedure is considered as meaningful. meanwhile the slt procedure is used as primary and supplementary treatment of glaucoma and study confirmed that the slt procedure was just as effective as administration of latanoprost in reducing iod in newly-diagnosed glaucoma.

Eligibility criteria:
inclusion criteria: patients with * primary open angle glaucoma (including normal tension glaucoma) * pseudoexfoliation glaucoma * pigment dispersion glaucoma exclusion criteria: previous intraocular surgery closed angle glaucoma pediatric glaucoma inflammatory or uveitic glaucoma unclear view of the trabecular meshwork

Keywords: glaucoma slt laser treatment iop glaucoma treated with eye drops but iop not controlled
a study of advanced or metastatic non-small cell lung cancer

Conditions: Non Small Cell Lung Cancer

Summary: the primary purpose of this study is to evaluate the efficacy and safety of ly2603618 in combination with pemetrexed and any side effects that might be associated with it along with determining the effects of ly2603618 in combination with pemetrexed in participants with advanced or metastatic non-small cell lung cancer (nsclc).


Eligibility criteria:
inclusion criteria: * must agree to have a tumor biopsy at screening * must have a diagnosis of advanced or metastatic non-squamous non-small cell lung cancer that has progressed after certain prior treatment * must be available for the duration of the study and willing to follow the study procedures * if participant is a woman that is capable of having children, must have a negative pregnancy test within 7 days of taking first dose of study drug * must have discontinued radiation therapy at least 4 weeks before entering this study exclusion criteria: * must not have taken an unapproved drug as treatment for any indication within the last 28 days before starting study treatment. * must not be pregnant or lactating, are considering becoming pregnant, or are considering fathering a child. males and females with reproductive potential must agree to use medically approved contraceptive precautions during the trial until the participant's physician considers it safe to become pregnant or father a child. * must not have known positive test in human immunodeficiency virus (hiv), hepatitis b surface antigen (hbsag), or hepatitis c antibodies (hcab). * must not have previously participated in a study involving ly2603618 * must not have previously taken pemetrexed for cancer * must not have a known allergy to ly2603618 or pemetrexed * must not currently have an infection that may affect participant's ability to tolerate the therapy * must not have a serious medical condition or disorder that would make it unsafe for you to participate in the study such as uncontrolled diabetes or chest pain due to heart disease * if taking certain medications called non-steroidal anti-inflammatory drugs (nsaids), such as ibuprofen, must be able to stop taking these medications according to certain guidelines
study investigating the use of intravenous fluids with dextrose for dehydrated children

Conditions: Gastroenteritis; Dehydration

Summary: infants and young children often become infected with gastroenteritis leading to vomiting and diarrhea. this can lead to dehydration, one of the most common complaints in the pediatric emergency department. these children are often in need of treatment with intravenous (iv) fluids. while the investigators know that iv fluids work, it is not clear which type or how much fluid is the best amount to give. currently, the most common type of iv fluid given is salt water, also called normal saline. in contrast to adults, infants and young children with dehydration often have a build up of a certain type of acid in their blood which can perpetuate the nausea, vomiting, and general malaise associated with gastroenteritis. the investigators feel that giving these children iv fluids with lots of sugar (in addition to the salt) reduces the acid more rapidly than giving just salt water alone. in a prior study, the investigators have shown that children who receive lower amounts of sugar in the iv fluids return to the emergency department more often for a second visit. based on this study, the investigators believe that children who receive the sugar-salt solution will do better than children who receive just normal saline. the investigators will determine if the sugar-salt solution is better by giving equal numbers of children the sugar-salt solution and normal saline and then see what happens to each child. the investigators will monitor who needs to be admitted, how much each child vomits, how much each child drinks, and also the level of acid in the blood before and after getting the iv fluid. after the study is completed, the investigators can compare the two different groups (children who received the sugar-salt solution versus children who received normal saline alone) to determine if one group had greater improvement and better clinical outcome than the other.


Eligibility criteria:
inclusion criteria: * 6 months to 6 years of age * gastroenteritis * requires iv fluids for dehydration exclusion criteria: * chronic disease * comorbid condition * received iv fluids or antiemetics in the last 12 hours * symptoms for more than 7 days * blood glucose less than 40
a pilot study of hemoporfin pdt in children(2-7 years old) with port-wine stain

Conditions: Port-wine Stain

Summary: this pilot study aims to evaluate the safety and efficacy of hemoporfin photodynamic therapy (pdt) with different light doses for port-wine stain (pws）in 2-7 years old children. the pharmacokinetic behavior and pharmacokinetic parameters of hemoporfin in children will be investigated as well.


Eligibility criteria:
inclusion criteria: * children with clinical diagnosis of pws； * ≥2 years old and \<7 years old； * the guardians agreed to voluntarily participate in this study and signed the informed consent agreement exclusion criteria: * therapy area located outside of head and neck; * other skin diseases that might interfere with the efficacy evaluation; * patients with respiratory disease, severe pulmonary dysfunction, history of airway hyperresponsiveness, or family history of suspected malignant hyperthermia; * preexist scars in the treatment area caused by previous treatment, which might interfere with the efficacy and safety evaluation; * with allergic diseases; known to be allergic to eggs, milk or soy protein; known to have skin photoallergies, porphyria or known allergic history of experimental drugs (porphyrins) and chemically structure similar drugs; known allergic history of anesthetics; allergic constitution; * cicatricial constitution; * immunocompromised conditions or need long-term use of glucocorticoids and immunosuppressive agents; * electrocardiographic abnormalities or organic heart diseases; * hepatic or renal functions abnormal (alanine aminotransferase or aspartate transaminase or total bilirubin \> 1.5 upper limit of normal \[uln\], or serum creatinine or blood urea nitrogen \> 1.5 uln); * coagulation disorders; * patients with severe neurological, psychiatric, endocrine and cardiovascular diseases; with epilepsy history or recent epileptic seizures; * be evaluated not suitable for anaesthesia by risk assessment before anaesthesia； * previous therapy of pws within the last 4 weeks; * participation in any clinical studies within the last 4 weeks; * be judged not suitable to participate the study by the investigators
a clinical trial to assess the effects of a vitamin shot on energy levels

Conditions: Energy; Fatigue; Mood; Weight Loss; Cognition

Summary: this is a virtual, single-arm clinical trial that will last 30 days. participants will drink 1 bottle of the vitamin energy® shot daily and complete questionnaires at baseline, day 7, day 14, and day 30. participants' energy, mood, and cognitive function will be evaluated at baseline and at each check-in. bodyweight will also be assessed at baseline and day 30. likert scale responses will be examined from baseline to each check-in. participant responses on product feedback will be presented as % scores.


Eligibility criteria:
inclusion criteria: men and women 18 years and over self-reported issues with: * energy * focus * brain fog participants who often feel fatigued willing to maintain the same caffeine consumption during the study period generally healthy - don't live with any uncontrolled chronic disease exclusion criteria: any pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders. anyone with known severe allergic reactions. women who are pregnant, breastfeeding, or attempting to become pregnant unwilling to follow the study protocol.